We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Truist raised the firm’s price target on Elevance Health (ELV) to $510 from $480 and keeps a Buy rating on the shares as part of a broader ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Barclays analyst Andrew Mok CFA maintained a Buy rating on Elevance Health (ELV – Research Report) today and set a price target of $512.00. The ...

Guggenheim just gave Elevance Health a shiny new Buy rating and a bold $518 price target, despite the current $430.90 tag.

Fintel reports that on April 9, 2025, Guggenheim initiated coverage of Elevance Health (NYSE:ELV) with a Buy recommendation.

Shares of Elevance Health Inc. ELV rallied 1.11% to $435.68 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to ...

A new law firm focused on supporting health tech and digital health companies has launched. | Elevare Law will work with ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $477.08, along with a high estimate of $512.00 and a low estimate of $405.40. Marking an ...